TABLE 3.

Comparison of SUV_max on FAP-2286 and FAPI-46 PET/CT Images in Primary and Metastatic Lesions

Parameter	n	Tumor size (cm)	Tracer	Positive lesions	SUVmax	P
Primary tumors (total)*	13	3.6 (1.0–6.2)	FAP-2286		13.6 (2.5–25.8)	0.53
			FAPI-46		13.3 (2.4–21.8)
Recurrence/mets
Recurrent tumor (total)†	4	3.1 (2.6–5.1)	FAP-2286	4	11.2 (2.7–14.4)	0.465
			FAPI-46	4	9.6 (2.9–13.6)
Lymph node mets (total)	33	1.2 (0.6–4.6)	FAP-2286	33	8.3 (3.4–15.6)	0.28
			FAPI-46	33	8.2 (4.0–15.4)
Lung mets	2	0.9 (0.8–1.0)	FAP-2286	2	4.0 (3.8–4.2)	NA
			FAPI-46	2	3.9 (3.6–4.2)
Hepatic mets	6	2.0 (0.9–11.8)	FAP-2286	6	4.6 (2.7–7.2)	0.345
			FAPI-46	6	4.4 (2.9–8.5)
Subcutaneous mets	10	0.8 (0.6–2.0)	FAP-2286	10	8.1 (7.4–10.3)	0.022
			FAPI-46	10	6.0 (3.6–8.6)
Peritoneal mets	22	NA‡	FAP-2286	22	9.8 (6–15.4)	0.18
			FAPI-46	22	11.4 (7.4–19.2)
Bone mets	10	1.3 (0.7–2.5)	FAP-2286	10	6.9 (3.9–12.2)	0.074
			FAPI-46	10	5.8 (2.9–11.4)

^*Primary tumors included head and neck cancer (n = 2), esophageal cancer (n = 1), lung adenocarcinoma (n = 1), hepatic cancer (n = 2), gastric cancer (n = 1), pancreatic cancer (n = 4), renal cancer (n = 1), and ovarian cancer (n = 1).

^†Including glioblastoma, tongue cancer, hepatic cancer, and gastric cancer.

^‡Because peritoneal metastases were statistically analyzed according to peritoneal cancer index score, size of lesions could not be obtained.

Mets = metastases; NA = not applicable.

Qualitative data are number; continuous data are median and range.